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Abstract
Objectives The aim of this study was to describe a
nationwide system for pre-marketing follow-up (cohort
temporary utilization authorization [ATU] protocol; i.e.,
‘therapeutic utilization’) of a new taste-masked formula-
tion of sodium phenylbutyrate (NaPB) granules (Phebura-
ne) in France and to analyze safety and efficacy in this
treated cohort of patients with urea cycle disease (UCD).
Methods In October 2012, a cohort ATU was established
in France to monitor the use of Pheburane on a named-
patient basis. All treated UCD patients were included in a
follow-up protocol developed by the Laboratory (Lucane
Pharma) and the French Medicines Agency (ANSM), which
recorded demographics, dosing characteristics of NaPB,
concomitant medications, adverse events, and clinical out-
come during the period of treatment. Following the granting
of the Marketing Authorization in Europe, the cohort ATU
was terminated approximately 1 year after its initiation, as
the product was launched on the French market.
Results The ease of administration and acceptability were
much better with the new taste-masked formulation than
with the previous treatment. No episodes of metabolic
decompensation were observed over a treatment period
ranging from 3 to 11 months with Pheburane and the
range of ammonia and glutamine plasma levels improved
and remained within the normal range. In all, no adverse
events were reported with Pheburane treatment.
Conclusions The recently developed taste-masked for-
mulation of NaPB granules improved the quality of life for
UCD patients. This may translate into improved compliance,
efficacy, and safety, which may be demonstrated either in
further studies or in the post-marketing use of the product.
Key Points
Sodium phenylbutyrate (NaPB) is a well known
long-term treatment of urea cycle disease (UCD)
NaPB has an offensive odor and taste which may
compromise compliance
Because of difficulty taking the active principle,
patients are often administered the drug via
nasogastric or gastrostomy tube
Pheburane is a new effective taste-masked
presentation of NaPB
This study reports the 1-year clinical experience of
patients with UCD with a new tasteless formulation
of NaPB in situ
The experience is positive on efficacy and safety
endpoints
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1 Introduction
It is evident that in rare disorders, new drugs not yet
approved for marketing must be monitored for safety and
effectiveness in the everyday clinical setting. The named
patients programs, and in particular in France the cohort
temporary utilization authorization (cohort ATU) pro-
gram, serve this purpose. Sodium phenylbutyrate (NaPB),
the unmodified active principle in Pheburane, has been
in clinical use for many years and its safety and efficacy
as a waste nitrogen alternative to urea nitrogen in the
treatment of urea cycle disorders is well established [1].
Other new derivatives with distinct pharmacological
characteristics (e.g., glyceryl tributyrate) [2] have been
developed to overcome the well known taste issue of
NaPB. Our aim in this paper is to report the findings of a
nationwide cohort ATU for patients with urea cycle dis-
orders (UCD) treated with a tasteless formulation of
NaPB, Pheburane, between October 2012 and October
2013.
UCD are extremely rare inherited deficiencies of one
of the enzymes involved in the cycle for the removal of
nitrogen produced from protein breakdown. In France, the
current estimate is approximately 40 patients under
treatment with NaPB granules amongst a total of about
100 patients with UCD receiving NaPB. The pharmaco-
logical treatment of UCD centers on alternative nitrogen
scavenging pathways where hippurate and phenylacetyl-
glutamine, the respective metabolites of benzoate and
NaPB, substitute to urea for waste nitrogen excretion [3].
Sodium phenylbutyrate has been used since 1987 as an
investigational new drug (IND) and was approved for
marketing in the US in 1996 and in the European Union
in 1999. Two presentations (both uncoated) were avail-
able: 500 mg tablets and powder/granules 94 % w/w. It is
well recognized that NaPB has a notoriously offensive
taste [1, 4]. This has been confirmed by electronic tongue
and real-time dissolution in vitro studies as well as by
studies in healthy volunteers [5]. In September 2012, the
French medicines agency (ANSM) granted a cohort ATU
for a tasteless oral granule formulation of NaPB, Phebu-
rane, allowing its use in UCD patients who could not
tolerate the marketed product due to its unpalatability.
The pharmaceutical company (Lucane Pharma) had the
opportunity to give input to and review the cohort ATU
protocol. Pheburane was granted market authorization in
the EU on 31 July 2013 and the ANSM advised that the
last date for inclusion in the cohort ATU should be 31
October 2013. Hence, the cohort ATU has spanned a
period of 1 year.
2 Methods
2.1 Patient Inclusion
Inclusion of patients in the cohort ATU protocol required
the diagnosis and treatment of UCD initiated by one of the
national reference centers of inherited metabolic diseases.
All patients with UCD are treated at a similar level of
healthcare—by pediatrician specialists with knowledge in
the management of UCD. The patient should have been
previously treated with at least one oral nitrogen scavenger
(NS). The NS could have been either the marketed NaPB
medication or sodium benzoate. In the latter case, before
being admitted to the cohort ATU protocol, administration
of the marketed NaPB product had to be attempted.
2.2 Switch Protocol
If admitted, patients could then be switched from the
product on the market to Pheburane. No systematic
examination was scheduled, patients being generally fol-
lowed up at the reference center every 6 to 12 months.
Because of the unscheduled follow-up, a possible a pos-
teriori finding was that, in spite of a request for inclusion,
patients (or their parents) had not complied with the cohort
ATU.
Every patient was identifiable by a unique personal
number issued by Lucane Pharma following the request for
inclusion of the patient in the cohort ATU made by the
treating physician together with the center’s pharmacist.
Patients/parents were informed about this inclusion by their
treating physician and all gave informed consent. Lucane
Pharma’s registries and sharing of patients’ personal
information were authorized by the ‘Commission Natio-
nale Informatique et Liberte´s’ (CNIL, authorization no.
1603498 v 0).
Prior to the development of Pheburane, a survey was
carried out in pediatric UCD patients receiving any of the
marketed formulations of NaPB, as authorized by the CNIL
(authorization no. DR-2012-505). This survey was aimed at
the evaluation of the palatability and ease or difficulty of
administration of the available medicine. The survey
included patient/parent questionnaires, as well as patients’
taste evaluations if possible. Evaluations of the global
acceptability of the taste were carried out using 100 mm-
visual analog scales (VAS) after repeated intakes of the
tested drug on 3 consecutive days. Some of the patients in
this survey were subsequently included in the cohort ATU
and the same evaluations of taste and global acceptability
were repeated with the patients/parents when receiving
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Pheburane. For the others, who generally tolerated the
existing formulation(s) of NaPB, clinical information is
also available and presented here. As the inclusion in the
future cohort ATU was not pre-determined, these latter
patients can be regarded as a control population. The
present paper also reports some of the taste and safety data
obtained during a study in healthy volunteers which
established the bioequivalence of Pheburane versus the
granule formulation of NaPB available on the market, and
has been previously reported [5]. In this cross-over study, a
comparative taste evaluation was carried out using VAS
ratings on global acceptance and three typical character-
istics of the taste (i.e., bitterness, saltiness, and sweetness)
which were repeated over three distinct time points: just
after, 30 minutes after and 2 hours after a single 5 g oral
dose of the study drug.
In the cohort ATU, data collection and reporting were
compulsory for all prescribers following approval of
inclusion by Lucane Pharma on behalf of the ANSM,
confirming compliance with the cohort ATU protocol.
2.3 Outcome Measures
Assessment of effectiveness was established from the
endpoints of acceptability, ease of administration of the
product, ranges of biological values (ammonia, glutamine)
and the number of hyperammonemia episodes.
The rating of acceptability (as well as that of bitterness
and other taste characteristics cf. above) was measured on
100 mm-VAS in healthy volunteers. In each individual the
difference in ratings following Pheburane minus licensed
product was calculated. In UCD patients, acceptability was
one item of a questionnaire completed by the treating
physician for inclusion of the patient in the cohort ATU.
Moreover, patients who had previously taken part in the
survey described above also repeated the questionnaire and
the acceptability VAS on 3 consecutive days when
receiving Pheburane.
A combined parameter of ‘ease of administration’ took
into account the need to reformulate the product and/or to
mix the product with taste flavoring agents such as calomel
syrup, and/or the need to use gastrostomy or nasogastric
tube for all or some of the daily intakes in order to
administer the product.
Finally, the numbers of episodes of hyperammonemia
during the previous 6-month period when receiving the
licensed NaPB formulation, compared with those reported
for the longest period of follow-up available with Phebu-
rane, were recorded together with the respective ranges of
laboratory values of ammonia and glutamine.
All patients recruited in the cohort ATU and all healthy
volunteers participating in the bioequivalence study were
included in the assessment of treatment safety. In the
bioequivalence study, adverse events were coded according
to the Medical Dictionary for Regulatory Activities
(MedDRA), Version 13.0. Recorded adverse reactions with
drug administration included, in particular, reports of taste
disturbances (dysgeusia or ageusia) and/or of vomiting,
regurgitation, or emesis at time of drug intake.
2.4 Statistical Analysis
The healthy volunteers’ taste assessments of the study
products were compared using an analysis of variance with
sequence, product, period, and product*period effects,
using SAS/STAT software with a two-sided 5 % signifi-
cance level. For the cohort ATU, the cut-off date for the
follow-up data was 31 December 2013, and mainly
descriptive statistics were applied using Excel software;
Wilcoxon’s tests were performed when appropriate.
3 Results
3.1 Acceptability of the Product in Comparison
with that of the Marketed Product
Following a single 5 g oral dose, there was a dramatic
increase in acceptability in 10 out of 13 healthy subjects
(Fig. 1). Only one subject has no value having withdrawn
from the study immediately after receiving the licensed
product. The analysis of variance of the differences of the
means was statistically significant (p \ 0.05).
From the mean (standard error [SE]) results of bitterness
(the main taste characteristic of NaPB) and general
acceptability (Fig. 2), it is clear that there was an inverse
relationship between general acceptability and bitterness
(correlation not tested). Mean acceptability increased by a
factor of two. At the same time, mean perceived bitterness
decreased by a factor of five.
The perception of taste characteristics of bitterness and
saltiness was significantly lower (p \ 0.05) just after the
dose of Pheburane than just after that of the licensed
product. As expected, measurement of sweetness was the
same with both products which indicates that the VAS
was discriminatory. Scores of bitterness, sweetness, or
saltiness at 30 minutes or at 2 hours after drug intake
were not significantly different between each drug (data
not shown).
A total of 26 patients from nine centers were proposed
for inclusion in the cohort ATU in order to receive
Pheburane. Of the 25 admitted (Table 1), 17 patients
(70 %) were included during the first half of the year and 8
during the second half. Because of reluctance from their
mother, two sisters who were requested cohort ATU
treatment were in fact not treated in one and only for
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1 week in the other. For an unknown reason, two siblings
were not treated despite request for inclusion in the cohort
ATU. Another patient was included in the cohort ATU but
actually not treated because of a different appreciation of
the actual need between treating physicians. Therefore
follow-up data are available in a total of 20 patients, the
majority (14) of whom have been switched from the NaPB
granule formulation on the market. Another male patient
presenting with a diagnosis of lysinuric protein intolerance
(LPI), and aged only 1 week, was denied inclusion on
safety grounds.
The UCD diagnoses included ornithine trans-carbamy-
lase deficiency (15), arginosuccinate synthase deficiency
(5), carbamoyl phosphate synthase type I deficiency (2),
arginosuccinate lyase deficiency (1), hyperornithinemia-
hyperammonemia-homocitrullinuria (1), and lysinuric
protein intolerance (1). There was a majority of female
patients (16). Clinical assessment at entry suggests that a
subset of patients had severe illness while the others were
mildly affected, with 7 patients presenting with neurologic
impairment or epilepsy, 11 with developmental delay, 6
with liver impairment, and 20 acute hyperammonemic
episodes in the 6 months before entering the cohort ATU in
a total of 10 patients (rate ranging between one and three
episodes/patient).
Pheburane was given orally in all patients at doses
between 1.5 and 15 g/day for 1–11 months; the mean (SD)
daily dose was 5.2 (3.3) g corresponding to 211 (112) mg/
kg at entry. The daily dose was administered in three or
four intakes per day as recommended. Mean (SD) exposure
to Pheburane was 15.0 (8.5) patient-years, as compared
with 50.9 (51.8) patient-years on marketed NaPB. Patients
were receiving the same co-medication as before once
treated with Pheburane. Co-treatment was with benzoate
(n = 15; mean [SE] dose = 5.7 [1.3] g/day), and/or cit-
rulline (n = 11; 4.2 [1.3] g/day) and/or arginine (n = 12;
1.6 [0.3] g/day).
The main entry criterion into the cohort ATU was the
unacceptability of the NaPB formulation(s) on the market.
The patient could either not take the drug (even if reformu-
lated) or required administration, for instance, via nasogas-




acceptability just after drug
intake in healthy volunteers
Fig. 2 Mean (SE) visual analogue scale ratings of acceptability and
bitterness just after drug intake in healthy volunteers, and accept-
ability in urea cycle disorder (UCD) patients
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of the prescribed dose was limited was difficulty with the
taste of NaPB. The marketed NaPB product was reported as
unacceptable in all 25 ATU patients. Out of the 25 patients,
four reported that it was totally impossible to take marketed
NaPB and they were not treated with the latter product after a
challenge test with the marketed product confirmed that
these patients cannot accept it. A single patient out of 25
admitted to the cohort ATU reported difficulty with the
granularity of Pheburane on the first intake and suspended
treatment; however, Pheburane was secondarily resumed
with no such further problem. After 6 months of inclusion, a
single patient discontinued from the cohort ATU for a
reported issue with granularity. Comparative data available
from 9 UCD patients receiving doses of 2.5–10 g/day
highlight a dramatic change in acceptability, even more
pronounced than that in healthy volunteers (Fig. 2).
3.2 Ease of Administration
Before inclusion in the cohort ATU, when patients were
receiving the licensed NaPB product, its administration
required re-formulation into capsules (2/25), or through
Table 2 Differences in ease of
administration between
marketed NaPB and
Pheburane in UCD patients
Italicised value: patient included
but treated for less than a week
(see text for details)
GST Gastrostomy, NaPB
sodium phenylbutyrate, NGT
nasogastric tube, UCD urea
cycle disorders
Patient No Age (years) NaPB
daily dose
(g/day)
Before Pheburane Under Pheburane
1 4 2 NGT Normal, per os
2 7 3 NGT Normal, per os
3 6 4 Impossible to take NaPB orally
Treated with benzoate
Normal, per os
4 9 5 Difficult to take NaPB orally
Reformulation
Normal, per os
5 11 10 NGT Normal, per os
6 13 6 NGT Normal, per os
7 9 4.5 Difficult to take NaPB orally
Reformulation
Not treated
8 5 3 Difficult to take NaPB orally
Reformulation of NaPB tablets
Not treated
9 24 8 Impossible to take NaPB orally
Treated with benzoate
Normal, per os
10 4 3 Impossible to take NaPB orally Normal, per os
11 3 1.5 Difficult to take NaPB orally Normal, per os
12 6 5 Impossible to take NaPB orally
Treated with benzoate (difficult)
Normal, per os
13 6 2 Difficult to take NaPB orally Not treated
14 9 5 Difficult to take NaPB orally Treated less than a week
15 5 3 GST Normal, per os
16 6 1.5 Dose too low to compound easily Normal, per os
17 15 10 Difficult to take NaPB orally Normal, per os
18 33 3 Difficult to take NaPB orally Normal, per os
19 4 6 Difficult to take NaPB orally
Takes tablets
Not treated
20 22 8 Difficult to take NaPB orally Normal, per os
21 14 6 Difficult to take NaPB orally
Takes tablets
Normal, per os
22 64 15 Difficult to take NaPB orally Normal, per os
23 18 4.5 Difficult to take NaPB orally
Takes tablets
Normal, per os
24 4 3.5 Difficult to take NaPB orally
Treated with benzoate
Normal, per os
25 4 8 Not treated before Normal, per os
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nasogastric tube (4/25) or gastrostomy (1/25). Conversely,
no additional measure was required to administer Phebu-
rane, which is simply taken orally in all patients in the
ATU follow-up (Table 2).
3.3 Number of Hyperammonemic Episodes
In the cohort ATU, the number of hyperammonemic epi-
sodes decreased from 20 reported in 10 patients in the
previous 6 months under the licensed NaPB to zero in the
same patients over a period of 3–11 months treatment with
Pheburane (Table 3). The group of patients that had not
reported decompensations before Pheburane did not have
any decompensations since starting Pheburane either.
Moreover, the median ranges (IQR) of plasma ammonia
(NH3) and glutamine (Gln) values were significantly lower
after having switched from the NaPB on the market to
Pheburane, with values of 124 (68–221) and 1,027
(905–1310) vs 49 (39.5–54.5) and 845 (707–1075)
(p = 0.019 and p = 0.028, Wilcoxon’s test), respectively,
in 11 ATU patients with before/after measures of these
biochemical parameters following 7 and 4 months’ treat-
ment. As assessed by the maximal plasma ammonia and
glutamine levels reported in the period before instauration
of Pheburane and during the follow-up under the drug, the
metabolic control appears to be significantly improved with
Pheburane (Fig. 3).
3.4 Taste Disturbance and Vomiting
In the healthy volunteers study there were 5/14 reports of
taste disturbance and 1/14 of severe vomiting after the
marketed product compared with 0/13 after Pheburane
(one female subject dropped out immediately after severe
vomiting following the marketed product during the first
period of the trial).
In the ATU, no patient has reported any adverse event,
notably no vomiting following administration of Phebura-
ne has been reported. This is in contrast to 4/25 patients
complaining of vomiting reflexes when receiving marketed
NaPB prior to entry into the cohort ATU.
4 Discussion
The new granule formulation of NaPB (Pheburane) has
been shown to be effectively taste-masked as demonstrated
in vitro as well as in healthy volunteers [5, 6]. These
studies confirmed that the coating on the Pheburane
granules was effective in preventing the active substance
from interacting with the taste receptors before swallowing.
As shown in three out of four control subjects not included
in the cohort ATU (survey data not shown) with the use of
crushed and/or encapsulated tablets, the historical product
is acceptable as long as the daily dose is not too high and





(in previous 6 months)
Under Pheburane
(exposure duration)
5 11 3 None (6 months)
9 24 1 None (11 months)
10 4 2 None (11 months)
11 3 2 None (10 month)
17 15 1 None (8 months)
20 22 1 None (6 months)
22 64 3 None (3 months)
23 18 2 None (3 months)
24 4 1 None (3 months)
25 4 3 None (3 months)
NaPB sodium phenylbutyrate
Fig. 3 Box–whisker plots of
maximal plasma ammonia
values in the 6-month period
before inclusion in the cohort
ATU and then under
Pheburane
Survey of Taste-Masked Sodium Phenylbutyrate in Urea Cycle Disorders 413
the age of the patient is compatible with swallowing tablet
formulations. However, data from the cohort ATU in
comparison with historical treatment characteristics indi-
cate that the quality of life of UCD patients and their
families has greatly improved with Pheburane as assessed
on the ease of administration of the drug and on the
meaningfully reduced incidence of adverse events, notably
vomiting and dysgeusia, which impair patients’ well-being
and/or their acceptance/compliance with pharmaceutical
treatments. Patients who cannot be treated with NaPB or
had to use alternative methods (reformulation, nasogastric
tube, and gastrostomy) were treated with Pheburane in the
cohort ATU without any problem, representing a dramatic
improvement in the care and the ability to use the appro-
priate prescribed and registered medication (NaPB) for
these children. The product was simply and normally taken
by mouth in all patients in the cohort ATU follow-up as
well as in 4/4 patients under other countries’ national
named patient programs (data not shown). Safety of the
drug is excellent as also confirmed from experience in
other patients in Sweden and in Turkey (personal com-
munication) who received Pheburane under a named
patients program prior to marketing approval.
It has been reported that taste disturbance is associated
with oral ingestion of NaPB. This adverse event and
vomiting associated with drug intake constitute unpleasant
adverse events, and both are reported as ‘frequent’ in the
Summary of Product Characteristics (SmPC) of NaPB [7].
Moreover, dysgeusia/ageusia can also compromise the
flavor of food, an additional problem in a UCD patient
where feeding is already very difficult due to restrictions in
the diet and need for supplementation.
Dysgeusia or vomiting at drug intake occurs, as shown,
even with single doses of NaPB. Other data supporting this
fact include the report of vomiting at intake of licensed
NaPB in one patient on a named patient program in Turkey
[8], in one control patient not included in the cohort ATU
(survey data not shown), as well as in one healthy volunteer
[5]. The absence of such vomiting reflex following drug
intake with Pheburane obviates the need for re-dosing and
therefore the risk of overdose, or the risk of under-dosing
should the dose not be re-administered adequately. As a
consequence, though this could not be demonstrated in the
cohort ATU given the limited number of patients and
duration, fewer adverse effects of over/under-dosing might
be expected with Pheburane.
Analysis of concomitant drug treatment showed a high
proportion (*60 %) of sodium benzoate users. This may
indicate that the NS treatment is carried out carefully by
prescribing a low total daily dose of licensed NaPB that is
bearable and actually approximately half that recom-
mended in the SmPC as seen before [9], together with
supplementation with benzoate. Whether the availability of
a taste-masked formulation of NaPB translates into higher
doses being able to be used and/or less use of benzoate
could not be assessed in the present cohort ATU. The
concomitant medications have not been modified in these
25 patients during the follow-up. Though 5/25 patients
(20 %) were given a higher dose of Pheburane than that
of licensed NaPB or were dose-increased within the follow-
up, it cannot be ascertained on such small numbers that this
was due to the more acceptable formulation.
The magnitude of the clinical effectiveness in this
nationwide pre-marketing cohort ATU program is similar
to the efficacy reported in previous clinical studies. In
seminal clinical trials of NS in UCD [10, 11] and other
long-term retrospective studies in ornityltranscarbamylase
deficiency (OTC) [12], surviving patients have presented
intercurrent episodes of hyperammonemia. For instance, in
a total of 97.6 patient-years of treatment (corresponding to
IND phases involving the specific use of NaPB), a total of
70 episodes were reported in 25 patients [10]. On average,
the surviving patients have had one episode per year;
however, the mean was 2.8 episodes/patient (and 0.7 epi-
sode/patient-year) showing a wide variability in the fre-
quency of episodes in individual arginosuccinate synthase
deficiency patients, as also observed in OTC [11]. In recent
studies, lower rates were reported, with 24 hyperammo-
nemic crises in 15 patients in the year under sodium
phenylbutyrate and 15 crises in 12 patients under glyceryl
tributyrate [13]. In the cohort ATU, the number of hyper-
ammonemic episodes decreased from 20 in 10 patients
(mean [SE] = 0.9 [0.4] and range 1–3 episodes/patient) in
the previous 6 months under the licensed NaPB—which
corresponds to figures observed before [10, 11, 13]—to
none over a period of 3–11 months’ treatment with
Pheburane. Though the cohort ATU protocol was not
designed to collect any measurement of compliance or
quality of life, the surrogate endpoint of decreased rate of
hyperammonemic decompensations may indicate a better
compliance and improved quality of life with Pheburane,
as also expected with other tasteless products [13, 14]. It is
possible that due to their inability to tolerate NaPB, the
patient cohort has been treated suboptimally prior to
treatment with Pheburane. Whether this is related to the
product’s characteristics, notably its absence of taste at
intake, or whether this is due to increased attention to
dosing due to inclusion in the cohort ATU cannot be
evaluated and warrants further studies.
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